Advisory - Pharmascience Inc. recalls one lot of prescription antifungal drug PMS-Nystatin Oral Suspension: Product may pose a choking risk
OTTAWA, Jan. 17, 2020 /CNW/ -
Summary
Product: PMS-Nystatin Oral Suspension 100,000 units/mL (DIN 00792667), Lot 681044, Expires 30-11-2021.
Issue: Product may contain clumps or jelly-like material, which may lead to choking. Newborns, infants and people with difficulty swallowing are particularly at risk.
What to do: If, even after the product is shaken well, your product still contains clumps greater than 1 millimetre in size or jelly-like material, return it to your pharmacy for safe disposal and to obtain a replacement.
Issue Health Canada is advising Canadians that Pharmascience Inc. is recalling one lot of PMS-Nystatin Oral Suspension, because it may contain clumps or jelly-like material that may pose a choking risk. Newborns, infants and people with difficulty swallowing are particularly at risk.
PMS-Nystatin Oral Suspension normally contains small visible particles and, as noted in the user instructions, it should be shaken well before each use to mix the drug evenly. For the affected lot, clumps greater than 1 millimetre (the size of a poppy seed) or jelly-like material may persist even after the product is shaken well.
Nystatin is a prescription antifungal drug for use by newborns, children and adults to treat and prevent fungal (candida) infections in the mouth, esophagus, stomach and intestinal tract.
Pharmascience Inc. notified Health Canada of this issue after receiving multiple complaints of clumps with the affected lot. Health Canada's laboratory testing of product samples also identified jelly-like material.
The affected lot was distributed throughout Canada starting in July 2019. To date, the company and Health Canada have not received any reports of adverse events involving this issue.
Who is affected Consumers who have bought or who are using the affected product.Newborns, infants and people with difficulty swallowing are particularly at risk.
Affected products PMS-Nystatin Oral Suspension 100,000 units/mL (DIN 00792667), Lot 681044, Expires 30-11-2021.
What consumers should do
Check whether your product is from the affected lot. If, even after the product is shaken well, the product still contains clumps greater than 1 millimetre in size (the size of a poppy seed) or jelly-like material, return it to your pharmacy for safe disposal and to obtain a replacement. Note: the product normally contains small visible particles even after it is shaken well, but the particles should not be greater than 1 millimetre in size.
If you are unable to identify the lot number (i.e., you received the product in a bottle other than the one shown in the photo below), and you have concerns about your product, contact your pharmacist.
Contact Pharmascience Medical Information by calling toll-free at 1-888-550-6060, or by emailing at [email protected], if you have any questions about this issue.
What Health Canada is doing Health Canada is monitoring the effectiveness of the company's recall and verifying that the company takes the necessary steps to prevent this issue from reoccurring.
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland.
The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance --
2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme").
For this purpose, Sobi has prepared a base prospectus, which...
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...